The Human Insulin Market is a "heavyweight" industry dominated by Novo Nordisk, Eli Lilly, and Sanofi, who together control nearly 90% of the global market by value in 2025. These giants are increasingly diversifying their portfolios into GLP-1 receptor agonists (like Ozempic and Mounjaro) which, while competing with insulin in early-stage Type 2 diabetes, are also being explored as...